Quality of life in clinical trials of adjuvant therapies. International Breast Cancer Study Group (formerly Ludwig Group).

R. D. Gelber, A. Goldhirsch, C. Hürny, J. Bernhard, R. J. Simes

Research output: Contribution to journalArticlepeer-review

Abstract

Clinical trials of adjuvant therapies usually measure the effectiveness of treatments by comparing disease-free survival or overall survival. These take into consideration only indirectly the quality of life experienced by the patients. We present some approaches that were developed to assess the impact of adjuvant therapy on the quality of life of breast cancer patients, as well as new methods created to compare treatments based on time spent without symptoms and toxicity (TWiST). The integration of these two methods (measuring quality and comparing duration of time) will provide a new tool for evaluating benefits from treatments given in the adjuvant setting.

Original languageEnglish
Pages (from-to)127-135
Number of pages9
JournalJournal of the National Cancer Institute - Monographs
Issue number11
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Quality of life in clinical trials of adjuvant therapies. International Breast Cancer Study Group (formerly Ludwig Group).'. Together they form a unique fingerprint.

Cite this